Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

The conversation humorously acknowledges the role of mice in testing Minoxidil for hair loss while also discussing the ethics of animal testing. Some users argue against animal testing, citing cruelty, while others defend its necessity for medical advancements.

Microneedling for hair loss involves sterilizing tools and possibly using serums like minoxidil or hyaluronic acid. Users report different routines, including applying minoxidil immediately after microneedling, using finasteride, and washing with ketoconazole shampoo.

Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

Mango oil may inhibit DKK1 and DHT, potentially aiding hair growth by activating the Wnt signaling pathway. A user plans to test mango leaves juice and other Ayurvedic products for hair regrowth.

Hair loss discussion involves ZeroMino from Minoxidilmax, with ingredients like Azelaic acid, Adenosine, Biotin, Caffeine, Niacinamide, Retinol, and Melatonin. Company refuses to disclose concentration of ingredients.

A user shared their 3-month hair growth progress using 1mg oral finasteride, 5% topical minoxidil, and microneedling with a 1.5 mm dermaroller twice weekly. The user received positive feedback and expressed a desire for thicker hair in the future.

User "hairlossblows" shares their positive experience with minoxidil, microneedling, and finasteride for hair loss treatment. They report significant hair regrowth, especially in the hairline, and minimal side effects from finasteride.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

The user has been using Minoxidil and finasteride with success and is now trying Dualgen-5R with retinoic acid but without finasteride, along with microneedling. They plan to share results in 5-6 months.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

The conclusion of the conversation is that the user, PirateBeastBaby, had good results with microneedling for hair loss after using oral finasteride and topical minoxidil 20 years ago. They believe that microneedling was the gamechanger for their hair growth.

Minoxidil may not be effective due to low sulfotransferase activity, and the user considers adding tretinoin to the regimen. They are unsure about the timing and combination with microneedling.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

A 22-year-old has been using minoxidil and finasteride for four years with limited success and recently added microneedling to their regimen. They have seen some hair regrowth and are advised to continue using minoxidil alongside microneedling and consider lifestyle factors like diet and stress.

Scientists discovered a sugar gel, 2dDR-SA, that increased hair growth in mice. Users discussed its potential, comparing it to other treatments like Minoxidil and finasteride.

A user did not respond to finasteride, dutasteride, and oral minoxidil for hair loss after four years of treatment and is considering scalp micropigmentation (SMP). Other users suggest the hair loss pattern may indicate alopecia areata and recommend seeing a dermatologist.

Microneedling for hair loss involves using a derminator pen at a depth of 1-1.5mm, typically once a week or biweekly, with a 12-24 hour wait before applying minoxidil. Cleaning involves alcohol wipes, and it's advised to change needles after each use and avoid styling products on the day of microneedling.

The user experienced hair regrowth using finasteride for 2 years, minoxidil for 2 months, and microneedling once a month. They reported no side effects and used 5% topical minoxidil in liquid form.

Microneedling can aid hair regrowth but poses risks like permanent hair loss if not done properly. Combining it with minoxidil, finasteride, and tretinoin, while ensuring proper sterilization and technique, is crucial for safety and effectiveness.

Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

The conversation is about hair regrowth using high-dose dutasteride, oral minoxidil, and microneedling. Users discuss seeing tiny hairs and hope they will become terminal, with advice to use derma rolling weekly for better results.